IRW-PRES: Heramed Limited: Heramed accelerates development program for the next AI generation
Highlights:
-Predictions for AI-controlled pregnancy prevention in Cald women (culturally and linguistically diverse groups) in cooperation with the Digital Health CRC and the RMI
– Template for AI assistant tool accelerated for doctors – First publication for Q4/2025 planned
O new functions starting with AI-supported ambient scribing to automate the documentation in patient care
– Innovative AI companion for digital support in women’s health – first application as voice assistant
– Basic developmental work for integration with leading EMR/Ehr system is driven – strategic growth path for 2026
– Expansion of the integration of Bluetooth-connected monitoring devices as well as developmental options for cellular devices to expand remote monitoring
– Customer upgrades from Heracare with AI dashboard and analytics to optimize work processes and user experience
Heramed Limited (ASX: HMD) (Heramed or the company), a leading provider in the field of pregnancy care and digital women’s health, is pleased to acquire the accelerated development and implementation of its AI-controlled technologies and central initiatives in the product plan of the Heracare platform. The accelerated implementation takes place in cooperation with existing and potential new customers and is accompanied by the strategic support of the Advisory Board.
Heramed pursues a multi -layered strategy to improve clinical results, optimize work processes and enable a scalable introduction of digital solutions for pregnancy care and women’s health worldwide. Heramed continues to position these further developments as a leading solution in the field of clinical remote monitoring in women’s health and create the basis for long -term scalable growth.
CEO CEO & Become Director von.
Everything we develop at Heramed is based on our claim to put our customers in the first place. The progress that we make – from AI -based health forecast to EMR integration and device compatibility – are based directly on the feedback from our health partners and doctors: inside. Every further development not only improves the quality of the care of women, but also increases market maturity and scalability of Heracare in health systems worldwide. I look forward to informing our investors: Inside the introduction of these functions and their positive influence for service providers and patients.
Vivek Krishhnan, member of the Advisory Board and Strategic Technologist, adds:
Heracare is already a strong, clinically validated platform. This development plan lifts them to a new level. We add components such as AI assistance for doctors, automation of workflows, connected devices and predictive health – and thus create an integrated ecosystem that puts Heramed at the top of digital health innovation. All of this is based on a responsible, inclusive and safe use of AI. With seamless EMR integration and growing device compatibility, Heracare will redefine digital pregnancy and women’s health worldwide.
The Heramed Technology Move combines all of these components into a comprehensive platform that addresses both short -term customer needs and creates the basis for long -term growth in the field of digital women’s health – starting with pregnancy care.
Next generation of AI assistance for doctors: automation of health workflows
Heramed has developed a new ambient scroll tool that will soon be available for the first time. It uses AI to automatically create structured consultation notes during virtual telemedicine dates. This tool reduces the administrative effort for doctors: inside, improves the documentation accuracy and will be seamlessly integrated into the electronic patient file (EMR) in the future.
It is important that the company has decided to accelerate the development of the AI assistance system- the first version is published in the 4th quarter of 2025 and includes automated note and workflow functions.
AI forecast model for pregnancy prevention at Cald women: project starts
In cooperation with the Digital Health Cooperative Research Center (CRC) and RMIT University, Heramed started the project. An expert body is currently under construction. The aim of the program is to develop AI-based health forecast models for risk pregnancies, especially for culturally and linguistically diverse population groups (balance). The first Proof-of-Concept models are expected in 2026 and form the basis for predictive functions in Heracare.
Innovative AI companion: scalable patient interaction
The company also develops a AI-based chat assistant for women’s health in order to strengthen patient integration and make administrative tasks in healthcare more efficient. This tool is the first phase of a AI-based virtual companion that will be expanded over the next 18 months.
Drive the EMR/Ehr-integration forward: for seamless work processes
Heramed continues to develop his EMR/Ehr-Base to enable integration with leading solutions. This commitment creates the basis for comprehensive possible uses for health service providers in the global sales network and makes Heracare a seamless, scalable solution within established EMR/ER-SYSTEMS.
Expansion of the ecosystem networked devices: from Bluetooth to mobile communications
Heracare expands the compatibility with medical devices for remote monitoring. In addition to Bluetooth-enabled devices, the support for cellular devices will also be provided in the future to enable integration with manufacturers in the lifestyle and clinic sector- including blood sugar measuring devices, heart rate monitors and blood pressure meters. This creates more flexibility and selection for health service providers.
AI-supported dashboard & analysis: More insight for clinic teams
The focus is on the continuous improvement of workflow and productivity. Based on customer feedback based on customer feedback, new AI functions in Heracare Analytic dashboard to provide doctors: Fast faster knowledge about patient loyalty, loyalty to therapy and clinical results.
END
HeraMED Limited
CEO & Managing Director:
Anoushka Gungadin
M: +61 431 131 649
E: anoushka@hera-med.com
CFO & Company Secretary:
Cameron Jones
T: +61 400 086 399
E: cameron.jones@bio101.com
Chairman:
Tim Chapman
T: +61 419 897 062
E: tchapman@claritycap.com.au
About Heramed Limited (ASX: HMD)
Heramed is an innovative medical technology and data company that thinks intelligent digital women’s health- in particular through the revolutionization of pre- and postnatal support by means of a hybrid supply platform. Heramed offers a proprietary platform that combines hardware and software to redesign the doctor-patient relationship. The basis is the clinically validated home device for monitoring fetal and maternal heart rate, supplemented by cloud computing, artificial intelligence and big data.
The company’s own platform Heracare was developed as a completely integrated ecosystem for mother-child health. The aim is to ensure better care at lower costs, to actively involve expectant mothers, to support medical specialists in quality assurance and to identify and avoid risks at an early stage.
Newsletter Registration:
Current press releases of this company directly in your mailbox:
Notification transmitted by irw-press.com. The sender is responsible for the content.
Free printing with source.
